Cellectis Presents Research Data On TALEN And TALEB Technologies For Gene And Cellular Therapies At ASGCT Annual Meeting
Monthly Information on Share Capital and Company Voting Rights
Cellectis S.A. Updates UCART Pipeline With Phase 2 Trial Details
European Equities Traded in the US as American Depositary Receipts Track Higher in Monday Trading
JMP Securities Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $6
Cellectis Reports 2024 Financial Results and Strategic Advances
Cellectis | 20-F/A: Registration statement / Annual report / Transition report (Amendment)
Cellectis SA: Strategic Collaborations and Clinical Advancements Drive Buy Rating
Cellectis | 20-F: FY2024 Annual Report
Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript Summary
Express News | Collectis Shares Are Trading Higher After the Company Reported Better-than-expected Q4 Financial Results
Cellectis CLLS Earnings; Shuttle Pharmaceuticals SHPH Offering
12 Health Care Stocks Moving In Friday's Pre-Market Session
Barclays Maintains Cellectis(CLLS.US) With Buy Rating, Maintains Target Price $5
Trending Stocks Today | Bit Origin Soars 45.29% Pre-Market
Why Rubrik Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket
Cellectis Q4 2024 Adj EPS $(0.16) Beats $(0.17) Estimate, Sales $33.22M Beat $9.45M Estimate
Press Release: Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
Cellectis 4Q Adj Loss/Shr 16c >CLLS
Cellectis 4Q Loss/Shr 17c >CLLS